|Bid||112.60 x 800|
|Ask||134.68 x 900|
|Day's Range||132.30 - 135.10|
|52 Week Range||90.64 - 141.25|
|Beta (3Y Monthly)||0.25|
|PE Ratio (TTM)||48.05|
|Earnings Date||Oct 23, 2019 - Oct 28, 2019|
|Forward Dividend & Yield||1.56 (1.17%)|
|1y Target Est||122.47|
ResMed today announced that David Pendarvis, chief administrative officer and global general counsel, will participate in a fireside chat at the 17th Annual Morgan Stanley Global Healthcare Conference on Monday, September 9, 2019, beginning at approximately 2:50 p.m.
ResMed (RMD) achieves double-digit global revenue growth in the fourth quarter, led by strong sales at Software-as-a-Service businesses as well as of new mask products and devices.
ResMed (RMD) delivered earnings and revenue surprises of 3.26% and 0.47%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Carlisle, Northrop Grumman, ResMed, T. Rowe Price and JetBlue Airways
MatrixCare announced today that Dheeraj Mahajan, MD, MBA, MPH, FACP, CMD, CIC, CHCQM, has joined its team as chief medical officer and executive vice president to advance MatrixCare’s vision of creating a seamless continuum where data moves with the patient, connecting both acute and post-acute care providers. Dr. Mahajan joins MatrixCare with more than 15 years as a practicing physician and is a nationally recognized expert and speaker on physician payment models, clinical documentation improvement, denial management, quality measurement in post-acute and long-term care, and transitional care quality improvement.
NEWPORT BEACH, Calif., July 15, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.
ResMed's (RMD) new product menu and an array of strategies are likely to benefit from the sleep-disordered breathing market. This should further drive its short-term performance.